A large number of myocytes are necessary to treat intractable muscular disorders such as Duchenne muscular dystrophy with cellbased\ntherapies. However, starting materials for cellular therapy products such as myoblasts, marrow stromal cells, menstrual\nblood-derived cells, and placenta-derived cells have a limited lifespan and cease to proliferate in vitro. From the viewpoints of\nmanufacturing and quality control, cells with a long lifespan are more suitable as a starting material. In this study, we generated\nstromal cells for future myoblast therapy from a working cell bank of human embryonic stem cells (ESCs). The ESC-derived\nCD105+ cells with extensive in vitro proliferation capability exhibited myogenesis and genetic stability in vitro. These results\nimply that ESC-derived CD105+ cells are another cell source for myoblasts in cell-based therapy for patients with genetic\nmuscular disorders. Since ESCs are immortal, mesenchymal stromal cells generated from ESCs can be manufactured at a large\nscale in one lot for pharmaceutical purposes.
Loading....